The second axis of the acute wound care segmentation is product type, which delineates the functional architecture of the market. Dressings constitute the core of the portfolio, representing roughly 55 % of global spend; within this class, sub‑categories such as hydrocolloid, alginate, foam, and film dressings are differentiated by exudate management, conformability, and barrier properties. Advanced therapies—including negative‑pressure wound therapy (NPWT), growth‑factor gels, and bio‑engineered skin substitutes—capture approximately 30 % of revenue, reflecting higher unit costs and clinical indications that demand accelerated granulation and reduced scarring. Antimicrobial agents (silver‑impregnated, iodine‑based, and honey‑derived dressings) account for the remaining 15 % and are valued for their infection‑prevention capability, especially in high‑risk surgical and traumatic settings. The relative weight of each type aligns with clinical practice guidelines and reimbursement structures, thereby shaping overall market size and growth trajectories. Consequently, manufacturers prioritize incremental innovation in high‑margin sub‑segments while maintaining broad distribution of low‑cost dressings to sustain volume.
